Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University/Rhode Island Hospital, 593 Eddy St, Providence, RI 02903.
Department of Radiology, Mayo Clinic, Rochester, MN.
AJR Am J Roentgenol. 2020 Aug;215(2):277-284. doi: 10.2214/AJR.19.22622. Epub 2020 Jun 17.
The purpose of this article is to review clinical uses and image interpretation of molecular breast imaging (MBI) and clarify radiation risks. MBI detects additional cancers compared with conventional imaging in women with dense breasts and those with elevated risk of breast cancer. Its role as an imaging biomarker of cancer risk and in assessing neoadjuvant chemotherapy response is growing. Radiation risk is minimal; benefit-to-risk ratio is similar to that of mammography. MBI is low cost, well tolerated, and easily adapted into clinical practice.
本文旨在回顾分子乳腺成像（MBI）的临床应用和图像解读，并阐明其辐射风险。与常规成像相比，MBI 可在致密乳腺和乳腺癌风险升高的女性中检测到更多的癌症。它作为癌症风险的影像学生物标志物以及评估新辅助化疗反应的作用正在不断发展。辐射风险极小；其受益与风险比与乳腺 X 线摄影相似。MBI 成本低、耐受性好，并且易于适应临床实践。
